Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference

Arrowhead Pharmaceuticals presented at the Cantor Global Healthcare Conference 2025 on September 4, 2025. The presentation was led by Prakhar Agrawal, a biotech analyst at Cantor. The conference focused on healthcare-related topics and provided a platform for Arrowhead to discuss its business and strategies.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented a strategic overview at the Cantor Global Healthcare Conference 2025, held on September 4, 2025. The company, led by CEO Chris Antalone, focused on transitioning to a commercial-stage enterprise with the anticipated approval of plozasiran. Key takeaways from the presentation included the company's robust pipeline, financial stability, and market positioning.

Arrowhead expects plozasiran to receive PDUFA approval in November, marking its shift to a commercial-stage company. The company is advancing its pipeline with MAPT and a PCSK9 ApoC3 dimer, targeting data readouts in 2026. Arrowhead is exploring partnership opportunities for its obesity program while emphasizing wholly-owned assets. Financially stable, Arrowhead has cash reserves to last into 2028, bolstered by milestone payments. The recent Novartis deal underscores the value of Arrowhead’s CNS platform.

Plozasiran is anticipated to secure a higher price point due to its potential in reducing pancreatitis risk. Arrowhead is financially secure with sufficient cash reserves projected to last into 2028. The company plans to continue business development activities to foster growth and innovation. Operational updates include the commercial team for plozasiran being fully installed and trained, ready for the anticipated launch. SHASTA-3 and SHASTA-4 trials are poised to showcase significant triglyceride reductions. MAPT and PCSK9 ApoC3 dimer are expected to enter clinical phases soon, with data anticipated in 2026. Arrowhead is pursuing both Inhibin E and ALK7 in its obesity program, with potential for combination therapies.

Future outlook includes Arrowhead initially targeting FCS and SHTG markets with plozasiran, with potential expansion into mixed dyslipidemia. The company is evaluating partnership opportunities for its obesity assets while maintaining focus on wholly-owned developments. Additional neuro assets are expected to enter the clinic in 2026, with ongoing collaborations such as the one with Novartis.

Arrowhead differentiates plozasiran by its superior triglyceride-lowering efficacy and less frequent dosing. The company is considering using Inhibin E and ALK7 in combination with existing therapies for sustained weight loss. Arrowhead aims to continue strategic partnerships while ensuring operational excellence.

References:
1. [Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference 2025](https://www.investing.com/news/transcripts/arrowhead-pharmaceuticals-at-cantor-global-healthcare-strategic-moves-and-market-positioning-93CH-4224703)
2. [Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Collaboration with Novartis](https://www.lawyer-monthly.com/2025/09/gibson-dunn-arrowhead-novartis-collaboration/)